Screener
Spyre Therapeutics, Inc. SYRE Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesFairValueDisclosure.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Level 1 | Level 2 | Level 3 | Total |
|---|---|---|---|---|
| U.S. government treasury securities | 257,180 | — | — | 257,180 |
| U.S. government agency securities | — | 136,040 | — | 136,040 |
| Commercial paper | — | 164,406 | — | 164,406 |
| Corporate bonds | — | 86,656 | — | 86,656 |
| Total financial assets | $352,628 | $387,102 | — | $739,730 |
| Liabilities: | ||||
| CVR liability | — | — | $56,950 | $56,950 |
| Total liabilities | — | — | $56,950 | $56,950 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s total liabilities?
- Spyre Therapeutics, Inc. (SYRE) reported total liabilities of $56.95M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total liabilities changed year-over-year?
- Spyre Therapeutics, Inc.'s total liabilities decreased by 34.7% year-over-year, from $87.17M to $56.95M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total liabilities?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total liabilities has grown at a 4.1% compound annual growth rate (CAGR), from $21.79M to $26.68M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Spyre Therapeutics, Inc.'s total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude